Menu
20 Apr 2026

HEUKING appoints Dr. Niclas von Woedtke as Equity Partner in Hamburg

"HEUKING hires Dr. Niclas von Woedtke as Equity Partner in Hamburg to bolster Venture Capital/M&A and Health Care & Life Sciences practices, focusing on biotech VC, spin-offs and investor transactions."

Dr. Niclas von Woedtke, MBA (45), will join HEUKING as an Equity Partner at the firm's Hamburg office effective May 1, 2026.

Von Woedtke joins from Taylor Wessing, where he advised on Corporate/M&A and established himself as a leading practitioner in venture capital transactions in the biotech sector. Prior to that, he worked at Boehringer Ingelheim and Otto Group.

His practice focuses on advising growth companies, with particular emphasis on spin-offs from corporates and universities in technology-driven and research-intensive fields. He also advises venture capital and venture debt investors on equity and debt investments throughout the entire company life cycle, including exits, and provides corporate and transactional advice to clients in the life sciences and healthcare sectors.

The appointment will further strengthen HEUKING’s Venture Capital/M&A and Health Care & Life Sciences practices. Von Woedtke will be based in Hamburg and will also work extensively from Munich, collaborating with colleagues from the firm’s Life Sciences team. In September 2025 a team of three female Equity Partners from Taylor Wessing in Munich, with whom von Woedtke had previously worked closely, joined HEUKING; that collaboration will now be continued and expanded.
Read the full story

Register for free to access daily news.

Register Free
We use cookies to improve your experience, analyze traffic, and serve targeted ads. Read our Cookie Policy.

Cookie Preferences

Customize your cookie settings. Necessary cookies are always enabled.

Strictly Necessary

Required for the website to function (e.g. login, security).

Analytics & Statistics

Help us understand how visitors interact with the website.

Marketing & Ads

Used to deliver relevant ads and track effectiveness.